Post hoc analysis of the DELIVER trial (890 adults with migraine after 2-4 failed preventives): among those first given eptinezumab, 23% had <4 monthly headache days in weeks 1-12 and 47% in weeks 61-72; 71% who fell below 8 days early stayed there.
Secondary analysisn = 890 adults
Tassorelli et al. Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2-4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial